Figure 1.
Olfactory proteotyping across Alzheimer’s disease (AD) and Parkinson’s disease (PD).
(A) Olfactory proteotyping approach to identify potential therapeutic targets and biomarkers. (B) Common deregulated targets across AD and PD stages. High AD: Braak V–VI stages; intermediate AD: Braak III–IV stages; low AD: Braak I–II stages; LBDN: Lewy body neocortical stage; LBDE: Lewy body early-neocortical stage; LBDL: Lewy body limbic stage.